88IV - PR Newswire Asia's news - Biotechnology

< Previous page

| Title only | Print

Next page >

Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026 Haier Biomedical Accelerates Its Transformation into an Intelligent Biopharmaceutical Infrastructure Platform at ISPE Singapore 2026 ... 2026-09-01T Biotechnology Medical/Pharmaceuticals
REJURAN COSMETICS Expands Across Canada with Nationwide Sephora Launch Premium derma-cosmetic brand from PharmaResearch, the Korean pharmaceutical company behind the globally recognized REJURAN® skin booster available in more than 50 countries, will launch in Sephora ... 2026-09-01T Biotechnology Cosmetics & Personal Care Medical/Pharmaceuticals
Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development NANJING, China , Sept. 1, 2026 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced that it has entered into an exclusive global licensing agreement ... 2026-09-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
QC Ware and IonQ Demonstrate High-Precision Hybrid Quantum Workflow for Drug Discovery Joint test on IonQ Forte hardware lands within 4% of benchmark, clearing the chemical-accuracy bar for enzyme active-site modeling via Amazon Braket ... 2026-09-01T Biotechnology Computer Hardware Computer/Electronics Health Care/Hospital
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction ... 2026-09-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity ... 2026-09-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel ROCKVILLE, Md. , Sept. 1, 2026 /PRNewswire/ -- OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the ... 2026-09-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
JIANGXI BIO Announced 2026 Interim Results Overseas Contract Orders Reach Nearly RMB27.4 mn and R&D Translation Gains Momentum, with the AEPC Platform Reshaping the R&D Paradigm for Equine Polyclonal Antibody ... 2026-09-01T Banking/Financial Service Biotechnology Chemical Health Care/Hospital
Singapore is the first ASEAN country to provide government subsidy for eligible patients receiving vutrisiran for transthyretin amyloidosis "From September 2026 – eligible patients receiving vutrisiran will receive government subsidies of up to 75% [1] , [2] " ... 2026-09-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering Company to host a corporate update call Tuesday, September 1st at 8:00am ET ... 2026-09-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved